News and Press Releases
PLL Therapeutics enrolls first patient in phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS)
Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo 140 ALS patients will participate in second stage of study to...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025
10 Avenue Roger Lapébie 33140 Villenave d’Ornon France
Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
4 April 2025 -- Valby, Denmark -- H. Lundbeck A/S (Lundbeck) to present positive interim results from the PACIFIC trial open-label extension investigating bexicaserin, in addition to new analyses from...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 4, 2025
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2025
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Rentschler Biopharma announces strategic realignment of its global business operations
30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...
Category: BioManufacturing
Posted: January 30, 2025
Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round
Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of...
Category: Drug Discovery
Posted: January 17, 2025
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
QurAlis Invited to Present at 43rd Annual J.P. Morgan Healthcare Conference
7 January 2025 -- Massaschusetts, US -- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 2, 2025
Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics
Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities 29 October 2024 -- New York, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: October 29, 2024
Owkin announces partnership with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer
2 October 2024 -- Paris, France -- Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 2, 2024
AzurBio Pharma Launches to Fast-Track European Market Entry for Biopharma Companies with Breakthrough Treatments
1 October 2024 -- Paris, France -- AzurBio Pharma, specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs, is...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 1, 2024
First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic
Proof-of-concept study to investigate personalised dose management of first-line anti-hypertensive in improving blood pressure control remotely Key milestone in co-development partnership to combine leading medicine brands with dose optimisation technology...
Category: Biotechnology, Clinical Trials
Posted: May 16, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
One2Treat launches ground-breaking treatment-decision approach to clinical research and market access analysis
One2Treat reflects patient priorities in a single comprehensive treatment evaluation, reducing trial sample size and accelerating patient access to new treatments 26 March 2024 -- Brussels, Belgium -- One2Treat, a...
Category: Clinical Trials, Pharmaceutical
Posted: March 26, 2024
